Answers are grounded in this paper and cite their sources.
OBJECTIVE: To provide an updated assessment of the efficacy, safety, and clinical outcomes of pharmacological treatments for Cushing's disease, focusing on cabergoline, ketoconazole, pasireotide, and osilodrostat. MATERIALS AND METHODS: This systematic review update was conducted using the Joanna Briggs Institute methodology. Outcomes included disease control rates, adverse events, and improvements in comorbidities and quality of life. RESULTS: Eleven new studies were included. In the updated analysis, disease control rates were 35.5% for cabergoline (95% confidence interval [CI]: 28-43%; 7 studies, 155 patients), 42% for ketoconazole (95% CI: 38-47%; 7 studies, 488 patients), 42% for pasireotide (95% CI: 28-58%; 10 studies, 580 patients), and 67% for osilodrostat (95% CI: 61-73%; 4 studies, 263 participants). According to GRADE, certainty of evidence was very low for pasireotide and low for the other agents. Osilodrostat increased cortisol normalization 4.56-fold versus placebo (95% CI: 1.53-13.56; 2 studies, 144 patients; moderate certainty). Osilodrostat and pasireotide improved CushingQoL scores by 13.23 points (95% CI: 10.78-15.68) and 8.96 points (95% CI: 4.37-13.55), respectively. Pasireotide was predominantly associated with dysglycemia. Cabergoline most often caused mild adverse events, with treatment escape in 11%. Ketoconazole was linked to mildly elevated transaminases and gastrointestinal symptoms. Osilodrostat most commonly resulted in fatigue and adrenal insufficiency, often reflecting therapeutic response. CONCLUSION: Pharmacological disease control rates in Cushing's disease range from 35.5% to 67%, with osilodrostat achieving the highest rates and being the only agent supported by placebo-controlled evidence demonstrating a statistically significant effect. In the absence of head-to-head comparisons, treatment decisions remain individualized.
No takes yet. Share an insight, caveat, or question.
Zimmermann et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: